The fact that our survival association was corroborated even using RNA-seq gene expression analysis as a surrogate for ultrahigh ERBB2 strongly suggests that increased ERBB2 CN may be associated to decreased benefit to adjuvant trastuzumab in primary BC. The gene discussed is ERBB2; the disease is breast cancer.